RANKL cDNA ORF Clone, Human, N-Myc tag

1/2
Price:
Size:
Number:

RANKL cDNA ORF Clone, Human, N-Myc tag: 製品情報

遺伝子
Human
遺伝子の長さ
999 bp
シーケンスの特徴
A number of silent mutations were introduced into the DNA sequence in order to increase its protein expression level in mammalian cell system. The translated amino acid sequence is identical with NP_003692.1.
製品の特徴
Full length Clone DNA of Human tumor necrosis factor (ligand) superfamily, member 11 with N terminal Myc tag.
プラスミド
プロモーター
Enhanced CMV promoter
ベクター
制限部位
HindIII + NotI(6kb+1kb)
タグシーケンス
Myc Tag Sequence: GAGCAGAAACTCATCTCAGAAGAGGATCTG
シークエンシングプライマー
T7( 5' TAATACGACTCACTATAGGG 3' )
BGH( 5' TAGAAGGCACAGTCGAGG 3' )
品質管理
The plasmid is confirmed by full-length sequencing.
スクリーニング
細菌スクリーニング抵抗力
Kanamycin
細胞スクリーニング抵抗力
Hygromycin
アプリケーション
Stable or Transient mammalian expression
保存 & 配送
配送方法
Each tube contains lyophilized plasmid.
保存条件
The lyophilized plasmid can be stored at ambient temperature for three months.

RANKL cDNA ORF ヌクレオチド配列およびアミノ酸配列に関する情報

**Sino Biological guarantees 100% sequence accuracy of all synthetic DNA constructs we deliver, but we do not guarantee protein expression in your experimental system. Protein expression is influenced by many factors that may vary between experiments or laboratories.**

RANKL cDNA ORF Clone, Human, N-Myc tag: 検証済の画像

RANKL cDNA ORF Clone, Human, N-Myc tag: 別名

CD254 cDNA ORF Clone, Human; hRANKL2 cDNA ORF Clone, Human; ODF cDNA ORF Clone, Human; OPGL cDNA ORF Clone, Human; OPTB2 cDNA ORF Clone, Human; RANKL cDNA ORF Clone, Human; sOdf cDNA ORF Clone, Human; TRANCE cDNA ORF Clone, Human

RANKL 背景情報

Tumor necrosis factor ligand superfamily member 11, also known as Receptor activator of nuclear factor kappa-B ligand, Osteoprotegerin ligand, TNFSF11, RANKL, TRANCE, OPGL and CD254, is a single-pass type II membrane protein which belongs to the tumor necrosis factor family. The receptor activator of nuclear factor-kappaB ligand (RANKL), its cognate receptor RANK, and its natural decoy receptor osteoprotegerin have been identified as the final effector molecules of osteoclastic bone resorption. RANK and RANKL are key regulators of bone remodeling and regulate T cell/dendritic cell communications, and lymph node formation. Moreover, RANKL and RANK are expressed in mammary gland epithelial cells and control the development of a lactating mammary gland during pregnancy. Genetically, RANKL and RANK are essential for the development and activation of osteoclasts and bone loss in response to virtually all triggers tested. Inhibition of RANKL function via the natural decoy receptor osteoprotegerin (OPG, TNFRSF11B) prevents bone loss in postmenopausal osteoporosis and cancer metastases. Importantly, RANKL appears to be the pathogenetic principle that causes bone and cartilage destruction in arthritis. RANK-RANKL signaling not only activates a variety of downstream signaling pathways required for osteoclast development, but crosstalk with other signaling pathways also fine-tunes bone homeostasis both in normal physiology and disease. In addition, RANKL and RANK have essential roles in lymph node formation, establishment of the thymic microenvironment, and development of a lactating mammary gland during pregnancy.
完全な名称
tumor necrosis factor (ligand) superfamily, member 11
参考文献
  • Takayanagi H, et al. (2002) Signaling crosstalk between RANKL and interferons in osteoclast differentiation. Arthritis Res. 4 Suppl 3: S227-32.
  • Nakashima T, et al. (2003) RANKL and RANK as novel therapeutic targets for arthritis. Curr Opin Rheumatol. 15(3): 280-7.
  • Schwarz EM, et al. (2007) Clinical development of anti-RANKL therapy. Arthritis Res Ther. 9 Suppl 1: S7.
  • Leibbrandt A, et al. (2008) RANK/RANKL: regulators of immune responses and bone physiology. Ann N Y Acad Sci. 1143: 123-50.
カートに追加しました カートに追加しませんでした カートを更新しています。少々お待ちください